Te Rēhita Mate Ūtaetae collects detailed data around the reporting of HER2 results and this enabled the HER2 negative tumours to be stratified into HER2-zero and HER2-low (acknowledging limitations [13,14,15]). The gene discussed is ERBB2; the disease is neoplasm.